MedTrace Logo

What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction

NCT03942692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2019-10-09

No results posted yet for this study

Summary

Anaphylaxis is an allergic reaction potentially fatal. The treatment is based on injection of epinephrin as soon as possible. Guidelines by the World Allergic Organisation highlight the importance of medical follow-up. This follow-up consists of an allergy consultation, the prescription and demonstration of epinephrin auto-injector and the implementation of specific measures in schools. There is no study about the recurrence of anaphylactic reaction outside the hospital.

The purpose of this study is to evaluate the allergy follow-up of children after anaphylactic reaction. The secondary objective is to evaluate the use of medical advice in case of recurrence of anaphylactic reaction.

Investigators will use a phone call questionnaire for parents of children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in the Paediatric Emergency Department in Femme-Mère-Enfant Hospital in Lyon in France. 179 children could be included in the study.

Conditions

Interventions

OTHER

Phone call questionnaire

Questionnaire for parents of subject about : * the frequency of consultations with an allergist * the information of the general practitioner or pediatrician * the prescription of epinephrin auto-injector * the frequency of renewal of epinephrin auto-injector * the specialty of doctor who prescribed the renewal * the implementation of specific measures in schools * the frequency of renewal of specific measures in schools * the number of recurrence of anaphylactic reaction * the use of medical advice in case of recurrence of anaphylactic reaction

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-21
Primary Completion
2019-08-20
Completion
2019-08-20

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942692 on ClinicalTrials.gov